Pipeline

Through BiMM technology, InnoTherapy has succeeded in developing a Hemostatic Pad with biocompatibility and an outstanding hemostatic capability. By expanding application of BiMM technology to biopharmaceuticals, the focus of research has extended to the development of a breakthrough technology that will overcome the limitations of conventional pharmaceutical development and go beyond the field of medical sealant.

Research

Non-clinical

Clinical

Approval

Bleeding

InnoSEAL

On-market   

Approval status

KR (2015, on market)

USA (2016), Japan (2018), Hongkong (2019), Pakistan (2019), Israel (2020), Argentina (2020)

Description

InnoSEAL is mainly used in Interventional Radiology and Cardiology for the purpose of hemostasis of the radial artery or femoral artery access site following non-invasive catheterization procedure. InnoSEAL is launched in number of international markets including USA and Japan.

InnoSEAL PLUS

  • Approval status
  • KR (2019)

Description

InnoSEAL Plus is an absorbable hemostatic pad., InnoSEAL Plus is the very first absorbable hemostatic product incorporating InnoTherapy’s technology, and the Ministry of Food and Drug Safety (MFDS) approval for a Class IV medical device was obtained in October 2019.

EndoSil

  • Approval status
  • KR (2019)

Description

EndoSil is an absorbable hemostatic agent used for the gastrointestinal oozing bleeding that may occur during endoscopic surgery. EndoSil is a hemostatic product that can also be used for organs of the digestive tract that pose difficulties due to unique mucosal tissues and gastric acid secretion. The product was developed as part of an effort to extend the scope of the InnoTherapy’s technology and the MFDS approval for a Class IV medical device was obtained in December 2019.

GellySil

Description

GellySil is a product achieving maximized convenience of use by combining a widely used biomaterial and the proprietary material developed by InnoTherapy. It is anticipated to serve as a versatile product that satisfies different needs in each surgical environment, especially where a long tube of laparoscopy or endoscopy is used in varying conditions

Leakage

Film
product

Description

Film-type surgical sealant is to complete sealing of anastomosis site. The product enables the sealing of anastomosis without disturbing the blood flow or peristalsis in the surgery of vascular or gastrointestinal anastomosis, as the tensile force of the biomaterial combines with the adhesive ability of InnoTherapy’s proprietary material

STOP
needle

Description

The STOP needle is coated with proprietary material and the needle can fundamentally block potential hemorrhage or infection from the puncture site when used in vascular injection. As the recent incidence of hospital-acquired infection has posed a significant threat to patients and medical practitioners, the potential demand for the STOP needle product is expected to be high.

STOP
needle
(ophthalmic)

Description

The STOP needle optimized for use in ophthalmology is a product that prevents potential leakage of the drug injected to the intraocular space to maintain the therapeutic level of the corresponding drug, thereby improving intended therapeutic effects. Among common eye disorders, macular degeneration is the condition for which a particularly large number of companies are developing a therapeutic agent, however, marketed drugs or those being newly developed are all extremely costly. The use of intraocular STOP needle is thus expected to allow an efficient treatment and consequently reduced economic burden.

Wound

Wound
dressing patch

Description

This product is a wound dressing that uses fish skin, which was developed via research on novel materials and outside conventionally used materials in product development. It can be applied to various wounds (chronic wounds, burns, etc.) with a role to absorb the wound exudate, prevent hemorrhage or loss of body fluid, protect the wound area, and facilitate healing.

Biomedicine

Gene therapy
(target delivery)

Description

One of the critical challenges imposed to gene therapy is the development of technology that enables gene therapy to be delivered to the target organ with lesion after i.v. injection (general administration route of gene therapy). Our patented material can bind to all kinds of proteins and be organ-specifically distributed after being systemically injected into body. We aim to tap into its unique features of our proprietary material to develop it as the universal delivery platform of gene therapy, especially in case of using AAV as a delivery vehicle, which is a big trend in the field of gene therapy development.